Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Aug;62(2):257–262. doi: 10.1038/bjc.1990.272

'JEB'--a carboplatin based regimen for malignant germ cell tumours in children.

C R Pinkerton 1, V Broadbent 1, A Horwich 1, J Levitt 1, T J McElwain 1, S T Meller 1, M Mott 1, A Oakhill 1, J Pritchard 1
PMCID: PMC1971831  PMID: 1696831

Abstract

Between February 1986 and July 1988 a total of 21 children aged 1 to 16 years with malignant germ cell tumours (MGCT), 18 with either metastatic disease or unresectable primary tumour, received the JEB regimen - carboplatin dosage calculated from the EDTA glomerular filtration rate (approximately 600 mg m-2), etoposide 120 mg m-2 daily x 3, and bleomycin 15 mg m-2 weekly. Primary sites were: testis (6), ovary (8), sacrococcyx (4), pineal gland (2) and vagina (1). AFP levels were elevated in 19, beta-HCG in 8. Complete marker response was achieved in 19 out of 19 evaluable patients and complete remission of measurable tumour in 16 out of 19, 12 with chemotherapy alone and 4 with the addition of surgery. A reduction in glomerular filtration rate greater than 10% occurred in 3 of 12 evaluable patients; in none greater than 20%. Sequential audiography was normal in 11 out of 12 evaluated. The regimen was myelosuppressive with WHO grade III or IV myelosuppression occurring in 12 patients. Three patients have relapsed; one with a pineal germinoma who relapsed in the abdomen six months after diagnosis, and two with sacrococcygeal teratomas and lung metastases. Two of these remain in second complete remission after further treatment. There was one death from probable bleomycin pulmonary toxicity. We conclude that this regimen is simple to administer and, apart from myelosuppression, it is well tolerated. It appears to have comparable efficacy to cisplatin-based regimens but with much less nephrotoxicity and ototoxicity and avoids the use of alkylating agents and anthracyclines.

Full text

PDF
257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brada M., Horwich A., Peckham M. J. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. Cancer Treat Rep. 1987 Jun;71(6):655–656. [PubMed] [Google Scholar]
  2. Brock P., Pritchard J., Bellman S., Pinkerton C. R. Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol. 1988;16(5):368–369. doi: 10.1002/mpo.2950160517. [DOI] [PubMed] [Google Scholar]
  3. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  4. Dalgleish A. G., Woods R. L., Levi J. A. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12(5):313–317. doi: 10.1002/mpo.2950120503. [DOI] [PubMed] [Google Scholar]
  5. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  6. Flamant F., Schwartz L., Delons E., Caillaud J. M., Hartmann O., Lemerle J. Nonseminomatous malignant germ cell tumors in children. Multidrug therapy in Stages III and IV. Cancer. 1984 Oct 15;54(8):1687–1691. doi: 10.1002/1097-0142(19841015)54:8<1687::aid-cncr2820540833>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  7. Horwich A., Brada M., Nicholls J., Jay G., Hendry W. F., Dearnaley D., Peckham M. J. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol. 1989 Feb;25(2):177–184. doi: 10.1016/0277-5379(89)90005-9. [DOI] [PubMed] [Google Scholar]
  8. Logothetis C. J., Samuels M. L., Selig D. E., Dexeus F. H., Johnson D. E., Swanson D. A., von Eschenbach A. C. Chemotherapy of extragonadal germ cell tumors. J Clin Oncol. 1985 Mar;3(3):316–325. doi: 10.1200/JCO.1985.3.3.316. [DOI] [PubMed] [Google Scholar]
  9. Newlands E. S., Begent R. H., Rustin G. J., Parker D., Bagshawe K. D. Further advances in the management of malignant teratomas of the testis and other sites. Lancet. 1983 Apr 30;1(8331):948–951. doi: 10.1016/s0140-6736(83)92079-2. [DOI] [PubMed] [Google Scholar]
  10. Peckham M. J., Barrett A., Liew K. H., Horwich A., Robinson B., Dobbs H. J., McElwain T. J., Hendry W. F. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer. 1983 May;47(5):613–619. doi: 10.1038/bjc.1983.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pinkerton C. R., Pritchard J., Spitz L. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy. J Clin Oncol. 1986 Feb;4(2):194–199. doi: 10.1200/JCO.1986.4.2.194. [DOI] [PubMed] [Google Scholar]
  12. Rustin G. J., Newlands E. S., Begent R. H., Dent J., Bagshawe K. D. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol. 1989 Jul;7(7):900–903. doi: 10.1200/JCO.1989.7.7.900. [DOI] [PubMed] [Google Scholar]
  13. Williams S. D., Birch R., Einhorn L. H., Irwin L., Greco F. A., Loehrer P. J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. [DOI] [PubMed] [Google Scholar]
  14. Womer R. B., Pritchard J., Barratt T. M. Renal toxicity of cisplatin in children. J Pediatr. 1985 Apr;106(4):659–663. doi: 10.1016/s0022-3476(85)80098-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES